ABSTRACT
In the treatment of breast cancer, axillary lymph nodes are a well-established marker of tumor metastasis and a target for removal, as axillary lymph node dissection (ALND) offers local control and decreases local recurrence. 1 However, ALND is associated with serious morbidity, including arm lymphedema, pain, and shoulder dysfunction. 2 Biopsy of sentinel lymph nodes (SLNs), which are the first lymph nodes to which a tumor drains, is now standard procedure for early stage breast cancers and has less morbidity compared with ALND. 3, 4 Because fewer nodes are typically submitted, they are sometimes examined in greater detail via a method such as step sectioning or immunohistochemistry, 4, 5 although pathology protocols vary between institutions. The increased scrutiny Upon completion of this activity you will be able to:
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in SLN evaluation increases the likelihood of detecting metastases, including micrometastases, defined as lesions between 0.2 and 2.0 mm, and isolated tumor cells, defined as lesions less than 0.2 mm and fewer than 200 cells. 6 While the prognosis and treatment associated with SLN macrometastases are fairly straightforward, findings of micrometastases or isolated tumor cells have been less clear regarding treatment, prognosis, and decision to perform an ALND. 7 The 2014 American Society of Clinical Oncology guidelines state that ALND should not be performed in women without any SLN metastases and should not be performed in women undergoing breast-conserving surgery with subsequent whole-breast radiation in which there are two or fewer SLNs with metastases. 8 Most breast cancer that is found on screening or biopsy specimens is invasive, but about one-fifth of detected cases is ductal carcinoma in situ (DCIS). 9 Because DCIS is noninvasive, it should, by definition, not metastasize. Nevertheless, a SLN biopsy (SLNB), in which one or more SLNs are removed, may be indicated for patients with DCIS if a mastectomy is performed (due to removal of the breast, rendering subsequent SLN identification difficult) or if the size of the suspected DCIS is large, as the area may harbor an intermixed invasive tumor. 8, 10 Indeed, about 25% of all patients with DCIS diagnosed via core biopsy have invasive breast carcinoma within the resection specimen.
11
Preliminary results for a SLNB can be obtained intraoperatively via frozen section to diagnose metastasis and provide information to determine whether an ALND needs to be performed concurrently with the resection procedure. 12 There is minimal information regarding the clinical utility of SLNB frozen section in patients with DCIS. A single study describing intraoperative frozen-section diagnosis of SLNs in patients with DCIS concluded that intraoperative examination is not necessary due to the low metastatic yield and low sensitivity of this technique. 10 In addition, eliminating frozen section of SLNB for DCIS has the potential to reduce health care expenditures. 10 We sought to investigate the frequency of use and clinical utility of SLNB frozen-section examination in mastectomies performed for DCIS at a single, large academic tertiary care center. Pathology resource utilization for SLNs submitted for DCIS was analyzed to determine the impact of frozen-section examination on pathology health care expenditures, and these data were compared with mastectomies for invasive breast carcinoma.
Materials and Methods
The pathology department database at The Ohio State University Wexner Medical Center was retrospectively searched for mastectomy resection specimens with SLNs submitted from January 2012 through December 2013 to the breast pathology service. Pathology reports were reviewed for patient diagnoses (both from biopsy and subsequent resection specimens), tumor characteristics (including data on SLN metastases), frozen-section performance and results, pathology resource utilization (number of SLNB parts submitted, blocks submitted, blocks frozen, and number of SLNs identified in submitted material), and surgeon performing the procedure. Cases were grouped based on whether they had invasive carcinoma or DCIS (without invasive tumor) diagnosed on previous biopsy specimens. Patients with bilateral resections who had bilateral malignancies and bilateral SLNB were categorized as having two specimens; patients with bilateral resections, bilateral malignancies, and only unilateral SLNB were categorized based on the laterality of the SLNB that was received.
Our institutional procedures for surgeon-requested SLNB cryosection include serial sectioning lymph nodes to a gross thickness of 0.2 cm, with three cryosections representing the first 20% of the tissue examined intraoperatively. Remaining tissue is submitted for permanent section, with examination of an additional two H&E levels and one intervening cytokeratin immunostain. If an intraoperative frozen section is not requested, three H&E levels and an AE1/3 cytokeratin immunostain between the first and second levels are examined.
The 2016 US Medicare allowable billing rates for the relevant Current Procedural Terminology (CPT) codes in the state of Ohio were used to estimate pathology health care expenditures due to the intraoperative frozen sections performed (including both technical and professional charges) and additional surgeon charges due to performing nonsynchronous ALND as follows: charge of first block frozen $92.67 (CPT code 88331), additional blocks frozen $48.79 (CPT code 88332), separate mastectomy and ALND $1,452.31 (CPT codes 19303 and 38525), and synchronous mastectomy and ALND $1,198.86 (CPT code 19307).
Data were catalogued and analyzed with χ 2 tests, Fisher exact tests, and logistic regressions performed in Stata version 13.1 (StataCorp, College Station, TX), as appropriate. For analyses comparing SLN parts per case, total SLN blocks per case, and total SLNs per case, a categorical system was used, in which cases with greater than five SLN part types, more than five SLN blocks per case, or more than five SLNs per case were grouped together for analysis.
Results
In total, 508 mastectomy specimens from 505 patients were identified during the 24-month time interval.
Procedures were performed by a total of six surgical oncologists. A total of 139 (27.4%) patients had a past diagnosis of DCIS alone. Imaging indications prior to biopsy diagnosis of DCIS included the following single cluster of suspicious calcifications, 51.8%; multiple clusters of suspicious calcifications without a mass, 23.0%; mass-like lesion or enhancement, with or without additional suspicious calcifications, 21.6%; and other, 3.6%. The remaining 369 (72.6%) specimens had either a biopsy diagnosis at our institution or a history of invasive breast disease. Of the 369 specimens with invasive disease on biopsy, resection specimens showed that 19 (5.1%) had no residual carcinoma (invasive or in situ), 13 (3.5%) had only DCIS remaining, and 337 (91.3%) had invasive mammary carcinoma, including 266 ductal carcinomas, 44 lobular carcinomas, and 27 other invasive carcinomas (11 with separate foci of ductal and lobular, six mucinous, four mixed ductal and lobular, two metaplastic, two adenoid cystic, one mucoepidermoid, and one high-grade neuroendocrine). Of the 139 patients with prior DCIS only, 96 (69.1%) had persistent in situ disease, 31 (22.3%) had invasive carcinoma, and 12 (8.6%) had no residual carcinoma (invasive or in situ) on resection.
The 508 mastectomy specimens had 1,645 corresponding SLNs identified ❚Table 1❚. The number of individually designated SLN parts submitted per breast ranged from one to eight (median, three), and total number of SLN blocks per case ranged from one to 23 (median, three). Total SLNs per case ranged from zero to 12 (median, three). Total number of blocks frozen per case ranged from zero to 11 (median, three).
Comparing cases with a history of DCIS to invasive carcinoma, frozen sections were requested by surgeons at a similar rate for patients with a history of DCIS and those with invasive disease (99.3% and 99.2%, respectively) (P = 1). In addition, there was no difference in number of SLN parts submitted, total SLN blocks frozen, total SLN blocks submitted, or total SLNs identified per case between invasive and DCIS groups (P = .633, .849, .710, and .394, respectively).
There was a significant difference in SLN positivity between cases with biopsy diagnoses of DCIS and invasive disease, with 6.5% (n = 9) of biopsy-diagnosed DCIS cases containing SLN metastases compared with 34.7% (n = 128) of biopsy-diagnosed invasive disease cases with SLN metastases (P < .001) ❚Table 2❚ and ❚Image 1❚. Five of the nine DCIS cases had invasive disease detected in the resection, while four cases had only in situ disease identified. All nine cases had SLNB sent for frozen section. Three (33.3%) contained macrometastases, all of which were identified at the time of frozen section. Two of the three cases with macrometastases identified at the time of frozen section had a synchronous ALND during the breast resection procedure. The remaining six cases had micrometastases (two cases, 22 at frozen section. No synchronous or subsequent ALND was performed on the third case with a macrometastasis or in the remaining six patients with micrometastases or isolated tumor cells. In the two cases with ALND, positive lymph nodes were only identified in SLNs, with the additional nodes from the ALND failing to yield positive nodes. In total, frozen-section examination affected surgical management in 1.4% (2/138) of mastectomies for DCIS. For comparison, frozen-section examination affected surgical management in 23.0% (84/366) of cases in the invasive carcinoma group. The pathology billing costs of frozen sections for both DCIS and invasive carcinoma were calculated ❚Table 3❚. An estimated cost of $132,632.55 was calculated for 1,584 blocks frozen with $38,625.30 for DCIS frozen sections and $94,007.25 for invasive carcinoma frozen sections. Based on the number of synchronous ALNDs completed that resulted from a positive frozen SLN ❚Image 1❚ Photomicrographs of cases from patients with a history of ductal carcinoma in situ and positive sentinel lymph nodes (SLNs) described in Table 2 . A, Case 3. SLN in which intraoperative frozen section was negative. Permanent section shown here contained isolated tumor cells (H&E, ×40) . B, Case 6. SLN in which intraoperative frozen-section examination was negative. Permanent section shown here revealed micrometastasis (H&E, ×10). C, Case 7. SLN in which intraoperative frozen section revealed a macrometastasis, shown here. An axillary lymph node dissection (ALND) was performed that did not contain additional positive nodes (H&E, ×10). D, Case 8. SLN in which intraoperative frozen section revealed a macrometastasis, shown here. No ALND was performed (H&E, ×20).
diagnosis, $19,312.65 was spent per patient with DCIS in which surgical management was affected, while $1,019.13 was spent per patient with invasive carcinoma in which surgical management was affected. Regarding estimated surgeon billing costs, there was a savings of $253.45 per patient in which a synchronous ALND was performed.
Discussion
DCIS is a theoretically nonmetastatic neoplasm of the breast, but DCIS diagnosed preoperatively may be upstaged to invasive breast cancer postoperatively and can even be found to have lymph node metastasis. Considerations for performing a SLNB with a history of DCIS include high tumor grade, large tumor size, and/or planned mastectomy procedure. Although intraoperative examination is not universally performed and techniques for screening vary, frozen sections on SLNs can be performed to identify lymph node metastasis. However, the presence of nodal metastasis in patients with a history of only DCIS is uncommon, raising the question of whether intraoperative SLN examination in this setting is of clinical value. Our current study evaluates the impact of intraoperative frozen-section examination of SLNs in a recent mastectomy cohort with DCIS diagnosed on needle core biopsy, analyzes the pathology-related resource utilization and expenditures, and compares these findings with invasive breast cancer.
At our institution, we found that there was no significant difference in the rate of intraoperative frozen-section usage between cases with a history of DCIS and invasive breast carcinoma (both 99%). In addition, we did not identify a difference in pathology resource utilization between DCIS and invasive breast carcinoma cases, including number of SLN blocks frozen, number of SLN blocks submitted, and total SLNs identified. To our knowledge, no prior publication has compared the rate of SLN intraoperative frozen-section usage or pathology resource utilization per case between DCIS and invasive breast cancer. We identified a mean of three SLNs per case for DCIS and invasive carcinoma, similar to prior reports of two for DCIS or two to three for invasive carcinoma. 10, [13] [14] [15] In our cohort, the rate of SLN positivity (inclusive of isolated tumor cells, micrometastases, and macrometastases) was 6.5% in patients with a history of DCIS and 34.7% for those with a history of invasive breast carcinoma. The impact of frozen-section SLN positivity (proportion of patients who received a synchronous ALND due to a positive frozen SLN) in patients with DCIS was rare (1.4%), while it was not uncommon in those with a history of invasive breast carcinoma (23.0%). Importantly, in the patients with a history of DCIS and a positive SLN identified by frozen section, the subsequent ALNDs performed based on the intraoperative examination did not yield any additional positive lymph nodes. In the research to date, the rate of positive SLNs in DCIS cases ranged from 0% to 10%, 10, 13, [16] [17] [18] [19] [20] and the rate in invasive cases was 15% to 39%. [14] [15] [16] [20] [21] [22] [23] [24] [25] In our cohort, the additional pathology cost due to performing frozen sections on SLNs was similar between those with a history of DCIS ($280) compared with invasive carcinoma ($257). However, the mean pathology expenditure per patient affected was substantially higher for patients with DCIS ($19,313) than those with invasive carcinoma ($1019), meaning that there were far more additional resources used to result in one patient receiving a synchronous ALND. Other studies have addressed total cost. One article with a cohort of 77 postoperative microinvasive breast carcinomas demonstrated that there was a potential to save $317 per patient, inclusive of additional operative and hospital costs, if frozen section was not done; in their cohort, there was one metastasis detected intraoperatively and one reoperation spared. 20 In another study, the total cost of frozen section in a cohort of 267 patients with DCIS was $443 per patient for pathologic examination and $743 per patient including operating room charges. 10 The mean pathology cost per patient receiving a synchronous ALND due to the results of a positive frozen-section SLNB was $39,410. 10 Our data, in combination with these two prior studies, give credence to the consideration of sparing frozen-section examination of SLNs in patients with DCIS.
In conclusion, intraoperative frozen-section examination of SLNs in patients undergoing mastectomy with a history of DCIS had an infrequent (1%) impact on intraoperative surgical management, and there was a substantially higher additional pathology frozen-section cost per case among patients with DCIS ($19,313) who received a 
